Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-26), Intellia Therapeutics's 3-1 Month Momentum % is -14.84%.
The industry rank for Intellia Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
NTLA's 3-1 Month Momentum % is ranked worse than 60.69% of 1389
companies
in the Biotechnology industry
Industry Median: -9.31
vs NTLA: -14.84
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Intellia Therapeutics 3-1 Month Momentum % Related Terms
NTLA vs SEPN, AVBP, VIR: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Intellia Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intellia Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Intellia Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intellia Therapeutics (NTLA) has a 3-1 Month Momentum % of -14.84% as of Aug. 26, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Intellia Therapeutics and its competitors. According to the industry distribution chart, Intellia Therapeutics ranks #843 out of 1389 companies in the Biotechnology industry, placing it in the top 60.7%.
Is Intellia Therapeutics' 3-1 Month Momentum % too high?
Intellia Therapeutics' current 3-1 Month Momentum % is -14.84%. Based on the distribution chart, Intellia Therapeutics ranks #843 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intellia Therapeutics has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' 3-1 Month Momentum % compare to SEPN and AVBP?
According to the Biotechnology industry distribution chart, Intellia Therapeutics ranks #843 out of 1389 companies for 3-1 Month Momentum %. This places Intellia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current 3-1 Month Momentum % is -14.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (NTLA) is currently considered Fairly Valued. The stock's GF Value™ is $13.49, compared to a current price of $13.51 — trading 0.1% above its estimated fair value. The current 3-1 Month Momentum % is -14.84%. Intellia Therapeutics' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Intellia Therapeutics (NTLA), the current 3-1 Month Momentum % is -14.84% as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intellia Therapeutics (NTLA) Overvalued in 2026?
Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be overvalued.
The current stock price of $13.51 is trading 0.1% above its estimated GF Value™ of $13.49.
GuruFocus considers Intellia Therapeutics to be Fairly Valued.
Key valuation signals for NTLA:
3-1 Month Momentum %: -14.84%
GF Value™: $13.49 vs. price of $13.51 (0.1% above fair value)
No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score
Get the complete analysis for NTLA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTLA has been successfully added to your 
